Together they aim to accelerate the development of therapies that work through RNA biology and engineered delivery methods to fix root genetic causes of disease, which Pfizer could apply to its portfolio of investigational programs.
MORE►
gene editing
Daniel Siegwart, Ph.D., is Director of the Program in Genetic Drug Engineering, Professor of Biomedical Engineering and Biochemistry, and a member of the Harold C. Simmons Comprehensive Cancer Center at UT Southwestern. [Photo: UT Southwestern]
UT Southwestern Collaborates With Pfizer to Develop Better RNA Delivery Tech
by Lance Murray | Feb 13, 2024
UT Southwestern Medical Center and pharmaceutical company Pfizer have teamed up to develop new ways to deliver genetic treatments to patients.
Together they aim to accelerate the development of therapies that work through RNA biology and engineered delivery methods to fix root genetic causes of disease, which Pfizer could apply to its portfolio of investigational programs.
Together they aim to accelerate the development of therapies that work through RNA biology and engineered delivery methods to fix root genetic causes of disease, which Pfizer could apply to its portfolio of investigational programs.
by Quincy Preston and Lance Murray |
Sep 19, 2023
With only two known living female northern white rhinos left, Colossal Biosciences and BioRescue have joined forces to fend off a looming extinction of the species. At the cutting edge of science, they're harnessing genetic technologies to rewrite the rhino's fate.
MORE►
by Quincy Preston |
Sep 18, 2023
The deal with Fresenius Kabi aims to bring innovative cell and gene treatments closer to patients by advancing Lupagen’s proprietary cell and gene therapy delivery system, the companies said. Their "to the bedside" approach could help open cutting-edge treatments to local hospitals and patients worldwide.
MORE►
by Lance Murray |
Dec 21, 2022
UT Southwestern researchers have used gene editing technology to develop what could be a breakthrough for dilated cardiomyopathy, a heart condition that affects one in 250 people worldwide.
“The pace of this field is really breathtaking,” said Eric Olson, Ph.D., who co-led the study. “I expect that if this moves forward into patients, we’re not talking within decades—we’re talking within years.”
MORE►
[Image: Paunuwach/istockphoto]
UT Southwestern-Linked Startup Exonics Therapeutics Exits in Deal Valued at $1B
by Lance Murray | Jun 17, 2019
The biotech company uses CRISPR technology licensed from UT Southwestern Medical Center in Dallas, and was co-founded by UTSW researcher and faculty member Eric Olson.
MORE►
by Lance Murray |
Sep 7, 2018
Also, you'll learn about advances to treat Duchenne muscular dystrophy and migraines. Here are some of the research projects underway in North Texas that could make lives better.
MORE►
